The global bioimpedance spectroscopy market was valued at US$ 469.8 Million in 2022 and is expected to reach US$ 1.4 Billion by 2033. The single-frequency bioimpedance spectroscopy segment with a market share of around 73.0% in 2022, has topped the global market within the product category and is expected to grow at a CAGR of close to 10.4% over the forecast period (2023 to 2033).
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 469.8 Million |
| Market Value 2023 | US$ 512.5 Million |
| Market Value 2033 | US$ 1.4 Billion |
| CAGR 2023 to 2033 | 10.4% |
| Market Share of Top 5 Countries | 54.6% |
| Key Market Players | Tanita Corporation, Akern, Biodynamics Corporation, Bioparhom, Biotekna, Bodystat Ltd, Charder Electronic Co. Ltd, Evolt 360, Fook Tin Group Holding Ltd, InBody Co. Ltd, Lumsail Industrial Inc., Maltron International, Omron Corporation, RJL Systems, Seca GmbH & Co. KG, SELVAS Healthcare Inc., Sino-Hero, Withings, ImpediMed Ltd. And Samsung. |
The electrical characteristics of biological tissues may be measured and analyzed using bioimpedance spectroscopy (BIS). A tiny current of electricity is sent across the human body while the resultant voltage is measured to assess several physiological characteristics. BIS can give useful information regarding the composition of the body, fluid distribution, cell membrane integrity, and tissue health by analysing impedance readings at numerous frequencies. In healthcare and scientific contexts, BIS is frequently used for applications such as measuring hydration status, tracking variations in body composition, measuring tissue health in disorders such as lymphedema, and directing treatment decisions. It provides a rapid, safe, and cost-effective approach to gaining useful information regarding an individual's state of health.
Overall, BIS is important for measuring and monitoring numerous aspects of human health, enabling personalized treatment methods, and optimizing patient care. BIS has proved useful for monitoring blood fluid variations, especially in post-surgical and HIV-infected patients. BIS, as a label-free, non-destructive, and simple-to-implement technology, has emerged as a potential experimental strategy in biological and medical applications such as biosensing technologies and disease diagnostics, including cancer and viral detection.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market recorded a historic CAGR of 8.3% in the last 5 years from 2017 to 2022. The market value for bioimpedance spectroscopy (BIS) was around 75.3% of the overall US$ 624.0 Million of the global body composition analyzers market in 2022.
The increasing prevalence of obesity can have a significant impact on this market. According to the data published by “World Obesity Atlas 2022”, it is estimated worldwide, out of 8 billion people, about 2.3 billion children and adults are estimated to be classified as overweight or obese. This points to the fact that obesity is a significant public health concern and accurate assessment of body composition is crucial for managing and treating obesity. Hence, the demand for body mass analyzers is anticipated to rise along with the number of obese people.
The increasing prevalence of obesity would likely lead to higher demand for body composition analysis tools like BIS. Other than this, increased healthcare spending on a global level may result in more acceptance and use of such technology. These parameters reflect a steady growth of this market in the coming years.
As healthcare professionals and patients are becoming more aware of the benefits of bioimpedance spectroscopy, there is an opportunity for increased use of this technique. BIS can provide valuable insights into a person's body composition, including muscle mass, fat mass, and fluid distribution. With the rising global prevalence of obesity and associated health concerns, there is a growing demand for accurate and non-invasive body composition assessment tools. BIS manufacturers can capitalize on this opportunity by developing advanced BIS devices that offer precise measurements and user-friendly interfaces.
This technology can help with the early identification, monitoring, and management of various disorders, resulting in better patient outcomes. According to the findings reported in the European Journal of Breast Health in May 2022, bioimpedance spectroscopy (BIS) seems helpful for earlier diagnosis of lymphedema associated with breast cancer. This presents lucrative opportunities for this market because the prevalence of breast cancer is quite high.
Principal Consultant
While bioimpedance spectroscopy has been shown to be effective in some areas, such as body composition analysis and fluid status evaluation, its applicability in other fields is still in the early stages. Bioimpedance spectroscopy data may be challenging to assess and integrate into clinical decision-making. BIS generates a significant amount of data and effectively interpreting and integrating this data into clinical decision-making processes can be a challenge. Healthcare providers may require training and support to leverage the full potential of BIS data for patient management. This would hamper the growth of the market in the forecasted period.
The lack of awareness and familiarity among healthcare professionals is a significant factor restraining the demand for bioimpedance spectroscopy (BIS). Limited knowledge about the capabilities and benefits of BIS hampers its adoption in clinical practice. Healthcare providers may be hesitant to invest in a technology they are not familiar with, leading to slower market growth.
The USA accounted for 89.5% market value share of the North American market in the year 2022. The USA healthcare industry fosters collaborations and partnerships between medical device companies, research institutions, and healthcare providers. These collaborations help drive the development, validation, and adoption of BIS technologies in the market.
USA has a high prevalence of chronic diseases. According to data published by CDC in 2022, six in ten Americans live with at least one chronic disease, like heart disease and stroke, cancer, or diabetes. BIS offers valuable insights into the assessment and monitoring of fluid status, body composition, and cellular health, making it relevant and in-demand for managing these chronic conditions.
Germany expenditure on bioimpedance spectroscopic diagnosis in 2022 was US$ 31.4 Million. Germany has a highly competent and well-trained workforce in healthcare, including physicians, researchers, and technicians. These experts are skilled in the use and interpretation of bioimpedance spectroscopy data, allowing the technique to be widely adopted and applied in clinical practice and research.
According to data published Journal of Health Monitoring in 2022, 53.5% of people in Germany are overweight, with 19.0% of adults in Germany having obesity. Further studies showed low education group exhibited higher prevalence of obesity than the high education group. This imbalance is critical in promoting the bioimpedance spectroscopy market in Germany.
In 2022, China held a dominant share of 38.7% in the East Asia. China is a predominant center for medical research and development. This increased spending provides opportunities for the adoption of advanced medical technologies, including BIS devices, in both clinical and non-clinical settings.
China has experienced a significant increase in obesity rates over the past few decades. Rapid urbanization, changing dietary patterns, sedentary lifestyles, and other socioeconomic factors have contributed to the rise in obesity. According to SHS Web of Conferences 2023, 49.1% of Chinese women aged 18-24 did not have a college education or higher degree. The prevalence of obesity was higher in Chinese socio-demographic groupings, creating an enormous demand for bioimpedance spectroscopy for obesity detection.
BIS technology can be utilized in various healthcare settings in China. This includes clinical settings for obesity management, monitoring fluid balance in patients with chronic conditions, and assessing body composition for personalized treatment plans.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Single frequency bioimpedance spectroscopy segment represented around US$ 342.7 Million market value in 2022.
There is no loss of information while measuring tissue hydration during fluid evacuation with HD using a single-frequency 50 kHz-impedance vector displacement. Bioimpedance analysis (BIA) via a single frequency current i.e. 50 kHz provides the most accurate insights at the tissue level because it maximizes the signal-to-noise ratio and minimises both frequency dependent errors and variability of electric flow paths. Single frequency bioimpedance spectroscopy is chosen over multi-frequency bioimpedance spectroscopy because of its high degree of accuracy.
By modality, the hand-held BIA accounted for a prominent share in the global bioimpedance spectroscopy market, with a revenue share of 56.7% in 2022. Hand-held BIA is a particularly convenient BIA approach and has been used for more than a decade.
In accordance with a study published in the Journal of Nutrients 2016, body fat percentage calculation using the hand-held BIA model in the standing posture was substantially linked with dual-energy X-ray absorptiometry-estimated body fat. In addition, the precision of the hand-to-hand BIA model findings was considerably higher than that of the hand-to-foot BIA model, indicating that the hand-to-hand BIA model in the standing position is practical for body composition evaluation. Therefore, the hand-held BIA segment dominates over other types of modalities in this market.
The hospitals have a considerable presence in the bioimpedance spectroscopy market, accounting for 47.8% of the market in 2022 and exhibiting a high CAGR of 9.5%. Hospitals provide comprehensive care facilities where patients receive multidisciplinary care. BIS technology can be integrated into the overall healthcare framework of hospitals, complementing other diagnostic modalities and treatments. The availability of BIS devices in hospitals enhances the range of tools and techniques healthcare professionals can utilize to deliver comprehensive patient care.
Collaborations and partnerships among healthcare providers, research institutions, and technology businesses can encourage innovation and hasten bioimpedance spectroscopy adoption. Collaboration in research, development, and commercialization can lead to market expansion and the creation of new applications. Numerous big tech giants and firms compete in the field of bioimpedance spectroscopy.
In comparison to other firms, Samsung has earned a technological advantage in BIS application, and the additional feature in its newly issued watch has helped develop an appealing feature in the heart of health-conscious consumers.
ImpediMed Ltd. developed digital health screening platform named SOZO for detection of lymphoedema. New guidelines were released by National Comprehensive Cancer Network (NCCN) for cancer care, cancer patients at risk of lymphoedema need to be screened at frequent intervals to identify early indications using symptom evaluation, clinical examinations, and BIS.
With technological advances in the medical sector bioimpedance spectroscopy will be useful in diagnosing breast cancer and measuring obesity, both of which are on the rise in the current time.
Similarly, recent developments related to the company’s manufacturing the bioimpedance spectroscopy have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Million for Value, Units for Volume |
| Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, France, Spain, Russia BENELUX, India, Indonesia, Thailand, Malaysia, China, Japan, South Korea, Australia, New Zealand, GCC Countries, Türkiye, Northern Africa and South Africa. |
| Key Market Segments Covered | Product, Modality, End User, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market is projected to generate US$ 512.5 million in sales by 2023.
The global market is set to be worth US$ 1.4 billion by 2033.
The market is estimated to advance at a 10.4% CAGR through 2033.
Opportunities for bioimpedance spectroscopy manufacturers include customized medicine, research adoption, and wearable health technology.
In terms of market value, the United States accounted for 89.5% of the North American market.
China controlled the East Asia market with a 38.7% share.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value-Added Insights
4.1. Product Adoption Analysis
4.2. Product USPs/Features Analysis, By Brands
4.3. Regulatory Landscape, By Country
4.4. Technology Advancements
4.5. Statistics of Diagnostic Techniques & Electrical Impedance Spectroscopy Technique
4.6. Porter’s Analysis
4.7. PESTLE Analysis
4.8. Value Chain Analysis
4.9. Unmet Needs
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure Outlook
5.1.2. Global Medical Device Market Outlook
5.1.3. Body Composition Analyzers Market Outlook (Parent Market Analysis)
5.2. Forecast Factors - Relevance & Impact
5.2.1. Growing awareness of early disease detection
5.2.2. Increasing prevalence of chronic diseases such as heart failure, kidney disease, lymphedema, and obesity
5.2.3. Technological advancements
5.2.4. Increasing demand for personalized medicine
5.2.5. New initiatives for product development
5.2.6. Growing acceptance in research and clinical settings
5.2.7. Cost of product
5.2.8. Increasing healthcare expenditure
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand Volume (Units) Analysis 2017 to 2022 and Forecast, 2023 to 2033
6.1. Historical Market Volume (Units) Analysis, 2017 to 2022
6.2. Current and Future Market Volume (Units) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
7. Global Market - Pricing Analysis
7.1. Regional Pricing Analysis By Product
7.2. Global Average Pricing Analysis Benchmark
7.3. Pricing Assumptions
8. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
8.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
8.2. Current and Future Market Size (US$ Million) Analysis and Forecast Projections, 2023 to 2033
8.2.1. Y-o-Y Growth Trend Analysis
8.2.2. Absolute $ Opportunity Analysis
8.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Product, 2017 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product, 2023 to 2033
9.3.1. Single Frequency
9.3.2. Multiple Frequency
9.4. Market Attractiveness Analysis By Product
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Modality
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Modality, 2017 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Modality, 2023 to 2033
10.3.1. Hand-held BIA
10.3.2. Hand-to-Foot BIA
10.3.3. Leg-to-Leg BIA
10.4. Market Attractiveness Analysis By Product
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis By End User, 2017 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033
11.3.1. Hospitals
11.3.2. Specialty Clinics
11.3.3. Ambulatory Surgical Centers
11.3.4. Rehabilitation Center
11.4. Market Attractiveness Analysis By Product
12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis By Region, 2017 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. South Asia
12.3.5. East Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. The USA
13.3.1.2. Canada
13.3.2. By Product
13.3.3. By Modality
13.3.4. By End User
13.4. Market Attractiveness Analysis By Region
13.4.1. By Country
13.4.2. By Product
13.4.3. By Modality
13.4.4. By End User
13.5. Market trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. USA Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Product
13.8.1.2.2. By Modality
13.8.1.2.3. By End User
13.8.2. Canada Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Product
13.8.2.2.2. By Modality
13.8.2.2.3. By End User
14. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Product
14.3.3. By Modality
14.3.4. By End User
14.4. Market Attractiveness Analysis By Region
14.4.1. By Country
14.4.2. By Product
14.4.3. By Modality
14.4.4. By End User
14.5. Market trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Brazil Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Product
14.8.1.2.2. By Modality
14.8.1.2.3. By End User
14.8.2. Mexico Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Product
14.8.2.2.2. By Modality
14.8.2.2.3. By End User
14.8.3. Argentina Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Product
14.8.3.2.2. By Modality
14.8.3.2.3. By End User
15. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction / Key Findings
15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. France
15.3.1.3. Spain
15.3.1.4. Russia
15.3.1.5. Italy
15.3.1.6. BENELUX
15.3.1.7. United Kingdom
15.3.1.8. Rest of Europe
15.3.2. By Product
15.3.3. By Modality
15.3.4. By End User
15.4. Market Attractiveness Analysis By Region
15.4.1. By Country
15.4.2. By Product
15.4.3. By Modality
15.4.4. By End User
15.5. Market trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Germany Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Product
15.8.1.2.2. By Modality
15.8.1.2.3. By End User
15.8.2. France Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Product
15.8.2.2.2. By Modality
15.8.2.2.3. By End User
15.8.3. Spain Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Product
15.8.3.2.2. By Modality
15.8.3.2.3. By End User
15.8.4. Italy Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Product
15.8.4.2.2. By Modality
15.8.4.2.3. By End User
15.8.5. BENELUX Market Analysis
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Product
15.8.5.2.2. By Modality
15.8.5.2.3. By End User
15.8.6. United Kingdom Market Analysis
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Product
15.8.6.2.2. By Modality
15.8.6.2.3. By End User
16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction / Key Findings
16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Indonesia
16.3.1.3. Thailand
16.3.1.4. Malaysia
16.3.1.5. Rest of South Asia
16.3.2. By Product
16.3.3. By Modality
16.3.4. By End User
16.4. Market Attractiveness Analysis By Region
16.4.1. By Country
16.4.2. By Product
16.4.3. By Modality
16.4.4. By End User
16.5. Market trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. India Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Product
16.8.1.2.2. By Modality
16.8.1.2.3. By End User
16.8.2. Indonesia Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Product
16.8.2.2.2. By Modality
16.8.2.2.3. By End User
16.8.3. Thailand Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Product
16.8.3.2.2. By Modality
16.8.3.2.3. By End User
16.8.4. Malaysia Market Analysis
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Product
16.8.4.2.2. By Modality
16.8.4.2.3. By End User
17. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction / Key Findings
17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Product
17.3.3. By Modality
17.3.4. By End User
17.4. Market Attractiveness Analysis By Region
17.4.1. By Country
17.4.2. By Product
17.4.3. By Modality
17.4.4. By End User
17.5. Market trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. China Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Product
17.8.1.2.2. By Modality
17.8.1.2.3. By End User
17.8.2. Japan Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Product
17.8.2.2.2. By Modality
17.8.2.2.3. By End User
17.8.3. South Korea Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Product
17.8.3.2.2. By Modality
17.8.3.2.3. By End User
18. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction / Key Findings
18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Product
18.3.3. By Modality
18.3.4. By End User
18.4. Market Attractiveness Analysis By Region
18.4.1. By Country
18.4.2. By Product
18.4.3. By Modality
18.4.4. By End User
18.5. Market trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. Australia Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Product
18.8.1.2.2. By Modality
18.8.1.2.3. By End User
18.8.2. New Zealand Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Product
18.8.2.2.2. By Modality
18.8.2.2.3. By End User
19. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033
19.1. Introduction / Key Findings
19.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Türkiye
19.3.1.3. South Africa
19.3.1.4. Northern Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Product
19.3.3. By Modality
19.3.4. By End User
19.4. Market Attractiveness Analysis By Region
19.4.1. By Country
19.4.2. By Product
19.4.3. By Modality
19.4.4. By End User
19.5. Market trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. GCC Countries Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Product
19.8.1.2.2. By Modality
19.8.1.2.3. By End User
19.8.2. Türkiye Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Product
19.8.2.2.2. By Modality
19.8.2.2.3. By End User
19.8.3. South Africa Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Product
19.8.3.2.2. By Modality
19.8.3.2.3. By End User
19.8.4. Northern Africa Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Product
19.8.4.2.2. By Modality
19.8.4.2.3. By End User
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players (%)
20.3. Market Presence Analysis
20.3.1. Regional Footprint of Players
20.3.2. Product Footprint of Players
20.3.3. Channel Footprint of Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Branding and Promotional Strategies By Key Players
21.3. Key Development Analysis
21.4. Competition Deep Dive
21.4.1. Tanita Corporation
21.4.1.1. Overview
21.4.1.2. Component Portfolio
21.4.1.3. Key Financials
21.4.1.4. Sales Footprint
21.4.1.5. Strategy Overview
21.4.1.5.1. Marketing Strategies
21.4.1.5.2. Channel Strategies
21.4.1.5.3. Product Strategies
21.4.2. Akern, Biodynamics Corporation
21.4.2.1. Overview
21.4.2.2. Component Portfolio
21.4.2.3. Key Financials
21.4.2.4. Sales Footprint
21.4.2.5. Strategy Overview
21.4.2.5.1. Marketing Strategies
21.4.2.5.2. Channel Strategies
21.4.2.5.3. Product Strategies
21.4.3. Bioparhom, Biotekna
21.4.3.1. Overview
21.4.3.2. Component Portfolio
21.4.3.3. Key Financials
21.4.3.4. Sales Footprint
21.4.3.5. Strategy Overview
21.4.3.5.1. Marketing Strategies
21.4.3.5.2. Channel Strategies
21.4.3.5.3. Product Strategies
21.4.4. Bodystat Ltd
21.4.4.1. Overview
21.4.4.2. Component Portfolio
21.4.4.3. Key Financials
21.4.4.4. Sales Footprint
21.4.4.5. Strategy Overview
21.4.4.5.1. Marketing Strategies
21.4.4.5.2. Channel Strategies
21.4.4.5.3. Product Strategies
21.4.5. Charder Electronic Co. Ltd
21.4.5.1. Overview
21.4.5.2. Component Portfolio
21.4.5.3. Key Financials
21.4.5.4. Sales Footprint
21.4.5.5. Strategy Overview
21.4.5.5.1. Marketing Strategies
21.4.5.5.2. Channel Strategies
21.4.5.5.3. Product Strategies
21.4.6. Evolt 360
21.4.6.1. Overview
21.4.6.2. Component Portfolio
21.4.6.3. Key Financials
21.4.6.4. Sales Footprint
21.4.6.5. Strategy Overview
21.4.6.5.1. Marketing Strategies
21.4.6.5.2. Channel Strategies
21.4.6.5.3. Product Strategies
21.4.7. Fook Tin Group Holding Ltd
21.4.7.1. Overview
21.4.7.2. Component Portfolio
21.4.7.3. Key Financials
21.4.7.4. Sales Footprint
21.4.7.5. Strategy Overview
21.4.7.5.1. Marketing Strategies
21.4.7.5.2. Channel Strategies
21.4.7.5.3. Product Strategies
21.4.8. InBody Co. Ltd
21.4.8.1. Overview
21.4.8.2. Component Portfolio
21.4.8.3. Key Financials
21.4.8.4. Sales Footprint
21.4.8.5. Strategy Overview
21.4.8.5.1. Marketing Strategies
21.4.8.5.2. Channel Strategies
21.4.8.5.3. Product Strategies
21.4.9. Lumsail Industrial Inc.
21.4.9.1. Overview
21.4.9.2. Component Portfolio
21.4.9.3. Key Financials
21.4.9.4. Sales Footprint
21.4.9.5. Strategy Overview
21.4.9.5.1. Marketing Strategies
21.4.9.5.2. Channel Strategies
21.4.9.5.3. Product Strategies
21.4.10. Maltron International
21.4.10.1. Overview
21.4.10.2. Component Portfolio
21.4.10.3. Key Financials
21.4.10.4. Sales Footprint
21.4.10.5. Strategy Overview
21.4.10.5.1. Marketing Strategies
21.4.10.5.2. Channel Strategies
21.4.10.5.3. Product Strategies
21.4.11. Omron Corporation
21.4.11.1. Overview
21.4.11.2. Component Portfolio
21.4.11.3. Key Financials
21.4.11.4. Sales Footprint
21.4.11.5. Strategy Overview
21.4.11.5.1. Marketing Strategies
21.4.11.5.2. Channel Strategies
21.4.11.5.3. Product Strategies
21.4.12. RJL Systems
21.4.12.1. Overview
21.4.12.2. Component Portfolio
21.4.12.3. Key Financials
21.4.12.4. Sales Footprint
21.4.12.5. Strategy Overview
21.4.12.5.1. Marketing Strategies
21.4.12.5.2. Channel Strategies
21.4.12.5.3. Product Strategies
21.4.13. Seca GmbH & Co. KG
21.4.13.1. Overview
21.4.13.2. Component Portfolio
21.4.13.3. Key Financials
21.4.13.4. Sales Footprint
21.4.13.5. Strategy Overview
21.4.13.5.1. Marketing Strategies
21.4.13.5.2. Channel Strategies
21.4.13.5.3. Product Strategies
21.4.14. SELVAS Healthcare Inc.
21.4.14.1. Overview
21.4.14.2. Component Portfolio
21.4.14.3. Key Financials
21.4.14.4. Sales Footprint
21.4.14.5. Strategy Overview
21.4.14.5.1. Marketing Strategies
21.4.14.5.2. Channel Strategies
21.4.14.5.3. Product Strategies
21.4.15. Sino-Hero
21.4.15.1. Overview
21.4.15.2. Component Portfolio
21.4.15.3. Key Financials
21.4.15.4. Sales Footprint
21.4.15.5. Strategy Overview
21.4.15.5.1. Marketing Strategies
21.4.15.5.2. Channel Strategies
21.4.15.5.3. Product Strategies
21.4.16. Withings
21.4.16.1. Overview
21.4.16.2. Component Portfolio
21.4.16.3. Key Financials
21.4.16.4. Sales Footprint
21.4.16.5. Strategy Overview
21.4.16.5.1. Marketing Strategies
21.4.16.5.2. Channel Strategies
21.4.16.5.3. Product Strategies
21.4.17. ImpediMed Ltd.
21.4.17.1. Overview
21.4.17.2. Component Portfolio
21.4.17.3. Key Financials
21.4.17.4. Sales Footprint
21.4.17.5. Strategy Overview
21.4.17.5.1. Marketing Strategies
21.4.17.5.2. Channel Strategies
21.4.17.5.3. Product Strategies
21.4.18. Samsung
21.4.18.1. Overview
21.4.18.2. Component Portfolio
21.4.18.3. Key Financials
21.4.18.4. Sales Footprint
21.4.18.5. Strategy Overview
21.4.18.5.1. Marketing Strategies
21.4.18.5.2. Channel Strategies
21.4.18.5.3. Product Strategies
22. Assumptions and Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Bioimpedance Spectroscopy Market
